Safety, Efficacy, and Bioavailability of Fixed-Dose Combinations in Type 2 Diabetes Mellitus: A Systematic Updated Review

Current Therapeutic Research - Clinical and Experimental

Volumn 84, Issue , 2017, Pages 4-9

  Vijayakumar, Thangavel Mahalingam ^a   Jayram, Jayasutha ^a   Meghana Cheekireddy, Vishnu ^a   Himaja, Dasari ^a   Dharma Teja, Yalamanchili ^a   Narayanasamy, Damodharan ^a  

^a SRM INSTITUTE OF SCIENCE AND TECHNOLOGY   (India)

Author keywords

bioavailability; fixed dose combinations; glycemic control; hyperglycemia; monotherapy

Indexed keywords

HEMOGLOBIN A1C; ORAL ANTIDIABETIC AGENT;

COMBINATION DRUG THERAPY; DIABETIC PATIENT; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; MEDICATION COMPLIANCE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW;

EID: 85018880292     PISSN: 0011393X     EISSN: 18790313     Source Type: Journal    
DOI: 10.1016/j.curtheres.2017.01.005     Document Type: Review

References (34)

1. Jung, S.H., Chae, J.W., Song, B.J., Kwon, K.I., Bioequivalence comparison of Two Formulations of Fixed-Dose Combination Glimepiride/metformin (2/500 mg) Tablets in Healthy Volunteers. IJPR 13 (2014), 365–371.
2. Park, S.I., Lee, H., Oh, J., Lim, K.S., Jang, I.J., Kim, J.A., Jung, J.H., Yu, K.S., A fixed-dose combination tablet of gemigliptin and metformin sustained release has comparable pharmacodynamic, pharmacokinetic, and tolerability profiles to separate tablets in healthy subjects. Drug Des. Dev. Ther 9 (2015), 729–736.
3. Ved, P., Shah, S., Evaluation of vildagliptin and fixed dose combination of vildagliptin and metformin on glycemic control and insulin dose over 3 months in patients with type 2 diabetes mellitus. IJEM 16 (2012), S110–S113.
4. Valensi, P., de Pouvourville, G., Bernard, N., Chanut-Vogel, C., Kempf, C., Eymard, E., Moisan, C., Dallongeville, J., Treatment maintenance duration of dual therapy with metformin and Sitagliptin in type 2 diabetes: The ODYSEE observational study. Diabetes Metab J 41 (2015), 231–238.
5. Wang, J.S., Huang, C.N., Hung, Y.J., Kwok, C.F., Sun, J.H., Pei, D., Yang, C.Y., Chen, C.C., Lin, C.L., Sheu, W.H., Acarbose plus metformin fixed-dose combination outperforms acarbosemonotherapy for type 2 diabetes. Diabetes Res ClinPract 102 (2013), 16–24.
6. Barner, J.C., Adherence to Oral Antidiabetic Agents with Pioglitazone and metformin: Comparison of Fixed-Dose Combination Therapy with Monotherapy and Loose-Dose Combination Therapy. Clin Ther 33 (2011), 1281–1288.
7. Boulton, D.W., Chang, M., Griffen, S.C., Kitaura, C., Lubin, S., Pollack, A., LaCreta, F., Fed and Fasted Single-dose Assessment of Bioequivalence of Dapagliflozin and Metformin Extended-release Fixed-dose Combination Tablets Relative to Single-component Dapagliflozin and Metformin Extended-release Tablets in Healthy Subjects. Clin. Ther 38 (2016), 99–109.
8. Hiroi, S., Matsuno, K., Hirayama, M., Hayakawa, T., Yoshioka, N., Kawakami, K., Evaluation of the bioequivalence of a fixed dose combination tablet of pioglitazone-metformin versus commercial tablets in healthy Japanese male volunteers. Diabetes Manag 2 (2012), 13–20.
9. Vanderpoel, D.R., Hussein, M.A., Watson-Heidari, T., Perry, A., Adherence to a Fixed-Dose Combination of Rosiglitazone Maleate/Metformin Hydrochloride in Subjects with Type 2 Diabetes Mellitus: A Retrospective Database Analysis. Clin.Ther 26 (2004), 2066–2075.
10. Bailey, C.J., Bagdonas, A., Rubes, J., McMorn, S.O., Donaldson, J., Biswas, N., Stewart, M.W., Rosiglitazone/Metformin Fixed-Dose Combination Compared with Uptitrated Metformin Alone in Type 2 Diabetes mellitus: A 24-week, Multicenter, Randomized, Double-Blind, Parallel-Group Study. Clin. Ther 27 (2005), 1548–1561.
11. ® (rosiglitazone and metformin hydrochloride). Full prescribing information, GlaxoSmithKline, Research Triangle Park, NC.2008. Available at: https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Avandamet/pdf/AVANDAMET-PI-MG.PDF. Accessed March 28, 2016.
12. Goldstein, B.J., Johnson, J., Feinglos, M.N., Williams-Herman, D.E., Lunceford, J.K., Effect of Initial Combination Therapy with Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, and Metformin on Glycemic Control in Patients with Type 2 Diabetes. Diabetes Care 30 (2007), 1979–1987.
13. ® (sitagliptin and metformin hydrochloride). Full prescribing information, Merck and Co, Whitehouse Station, NJ.2010. Available at: http://www.merck.com/product/usa/pi_circulars/j/janumet/janumet_pi.pdf. Accessed March 28, 2016.
14. González-Ortiz, M., Guerrero-Romero, J.F., Violante-Ortiz, R., Wacher-Rodarte, N., Martínez-Abundis, E., Aguilar-Salinas, C., Islas-Andrade, S., Arechavaleta-Granell, R., González-Canudas, J., RodríGuez-Morán, M., Zavala-Suárez, E., Ramos-Zavala, M.G., Metha, R., Revilla-Monsalve, C., Beltrán-Jaramillo, T.J., Efficacy of glimepiride/metformin combination versus glibenclamide/ metformin in patients with uncontrolled type 2 diabetes mellitus. J. Diabetes Complicat 23 (2009), 376–379.
15. Shin, K.H., Kim, S.E., Yoon, S.H., Cho, Jy, Jang, I.J., Shin, S.G., Yu, K.S., Pharmacokinetic Comparison of a New Sustained-Release Formulation of Glimepiride/Metformin 1/500 mg Combination Tablet and a Sustained-release Formulation of Glimepiride/Metformin 2/500 mg Combination Tablet in Healthy Korean Male Volunteers: A Randomised, 2-Sequence, 2-Period, 2-Tretament Crossover Study. Clin. Ther 33 (2011), 1809–1818.
16. Chien, H.H., Chang, C.T., Chu, N.F., Hsich, S.H., Huang, Y.Y., Lee, I.T., Lee, W.J., Tang, Y.J., Sheu, W.H., Effect of Glyburide-Metformin Combination Tablet in Patients with Type 2 Diabetes. Chin Med Assoc 70 (2007), 473–480.
17. ® (glyburide and metformin hydrochloride). Full prescribing information, Bristol-Myers Squibb, Princeton, Nj.2010. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021178s012lbl.pdf.
18. Rombopoulos, G., Hatzikou, M., Athanasiadis, A., Elisaf, M., Treatment Compliance with Fixed-Dose Combination of Vildagliptin/Metformin in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Metformin Monotherapy: A 24-Week Observational Study. Int J Endocrinol 2015 (2015), 1–15.
19. ® (pioglitazone hydrochloride and metformin hydrochloride extended-release). Full prescribing information, Takeda Pharmaceuticals America, Inc., Deerfield, IL, 2010. Available at: http://general.takedapharm.com/content/file.aspx?filetypecode=actoplusmetpi&cacheRandomizer=287cd1f9-1759-4901-a1d6-ac9f8d40db4e; http://general.takedapharm.com/content/file.aspx?filetypecode=ACTOPLUSMETXRPI&cacheRandomizer=8a7806a1-d545-425e-a478-3e3d17f50d6a. Accessed March 28, 2016.
20. Hoelscher, D., Chu, P.L., Lyness, W., Fixed Dose Combination Tablet of Repaglinide and Metformin is Bioequivalent to Concomitantly Administered Individual Tablets of Repaglinide and Metformin. Clin Drug Invest 28 (2008), 573–582.
21. ® (repaglinide and metformin hydrochloride). Full prescribing information, Novo Nordisk, Princeton, NJ.2010. Available at: http://www.novo-pi.com/prandimet.pdf. Accessed March 28, 2016.
22. Jung, J.A., Kim, J.R., Kim, S.R., Kim, T.E., Lee, S.Y., Ko, J.W., Huh, W., Pharmacokinetics of a Fixed-Dose Combination of Mitiglinide and Metformin versus Concurrent Administration of Individual Formulations in Healthy Subjects. Clin Drug Investig 32 (2012), 799–804.
23. Lewin, A., DeFronzo, R.A., Patel, S., Liu, D., Kaste, R., Woerle, H.J., Broedi, U.C., Initial Combination of Empagliflozin and Linagliptin in Subjects with Type 2 Diabetes. Diabetes Care 38 (2015), 394–402.
24. ® (glipizide and metformin hydrochloride). Full prescribing information, Bristol-Myers Squibb, Princeton, NJ.2009. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021460s007lbl.pdf. Accessed March 28, 2016.
25. ® (rosiglitazone and glimepiride). Full prescribing information, GlaxoSmithKline, Research Triangle Park, NC.2009. Available at: https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Avandaryl/pdf/AVANDARYL-PI-MG.PDF. Accessed March 28, 2016.
26. ® (pioglitazone and glimepiride). Full prescribing information, Takeda Pharmaceuticals America, Deerfield, IL.2010. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021925s010s011lbl.pdf. Accessed March 28, 2016.
27. ® (saxagliptin and extended-release metformin hydrochloride). Full prescribing information, Bristol-Myers Squibb, Princeton, NJ.2010. Available at: http://www.azpicentral.com/kombiglyze-xr/pi_kombiglyze_xr.pdf. Accessed March 28, 2016.
28. Balu, S., Simko, R.J., Quimbo, R.M., Cziraky, M.J., Impact of fixed-dose and multi-pill combination dyslipidemia therapies on medication adherence and the economic burden of sub-optimal adherence. Curr Med Res Opin 25 (2009), 2765–2775.
29. Gu, N., Kim, B.H., Rhim, H.Y., Chung, J.Y., Kim, J.R., Shin, H.S., Yoon, S.H., Cho, J.Y., Shin, S.G., Jang, I.J., Yu, K.S., Comparison of the Bioavailability and Tolerability of Fixed-Dose Combination Glimepiride/Metformin 2/500-mg Tablets Versus Separate Tablets: A Single-Dose, Randomized-Sequence, Open-Label, Two-Period Crossover Study in Healthy Korean Volunteers. Clin Ther 32 (2010), 1408–1418.
30. Saboo, Banshi, Chandrasekhara Reddy, Gundam, Juneja, Subhashchander, Kumar Kedia, Ashok, Manjrekar, Pravin, Rathod, Rahul, Effectiveness and safety of fixed dose combination of acarbose/metformin in Indian Type 2 diabetes patients: Results from observational GLOBE Study. IJEM 19 (2016), 129–135.
31. Rosenstock, J., Fleck, P.R., Inzucchi, S.E., Wilson, C.A., Seufert, J., Mekki, Q., Initial Combination Therapy with Alogliptin and Pioglitazone in Drug-Naïve Patients with Type 2 Diabetes. Diabetes Care 33 (2010), 2406–2408.
32. Derosa, G., Cicero, A.F., Gaddi, A.V., Ciccarelli, L., Piccinni, M.N., Salvadeo, S., Pricolo, F., Fogari, E., Ghelfi, M., Ferrari, I., Fogari, R., Long-term Effects of Glimepiride or Rosiglitazone in Combination with Metformin on Blood Pressure Control in Type 2 Diabetic Patients Affected by the Metabolic Syndrome: A 12-Month, Double-Blind, Randomized Clinical Trial. Clin Ther 27 (2005), 1383–1391.
33. Chang, M., Liu, X., Cui, D., Liang, D., LaCreta, F., Griffen, S.C., Lubin, S., Quamina-Edghill, D., Boulton, D.W., Bioequivalence, Food Effect and Steady-State Assessment of Dapagliflozin/Metformin Extended-release Fixed-dose Combination Tablets Relative to Single-component Dapagliflozin and Metformin Extended-release Tablets in Healthy Subjects. Clin Ther 37 (2015), 1517–1528.
34. Migoya, E.M., Miller, J.L., Gutierrez, M., Zheng, W., Johnson-Levonas, A.O., Liu, Q., Matthews, C.Z., Wagner, J.A., Gottesdiener, K.M., Bioequivalence of Sitagliptin/Metformin Fixed-Dose Combination Tablets and Concomitant Administration of Sitagliptin and Metformin in Healthy Adult Subjects. Clin Drug Investig 30 (2010), 855–866.